Alterity Therapeutics (ASX:ATH) has announced that the first participant has been dosed in the United Kingdom in the company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy. …
Alterity Therapeutics enrols first patient in trial of ATH434 for Multiple System Atrophy
April 4, 2023 Australian Biotech
Latest Video
New Stories
-
Australian researchers solve decades-long mystery on Parkinson’s disease
March 14, 2025 - - Australian Biotech -
Kosi climbers about to embark on day one of 2025 challenge
March 14, 2025 - - Latest News -
Astellas cancer therapy approved for new indication in earlier prostate cancer
March 14, 2025 - - Latest News -
World-first study identifies 'Goldilocks' number of genes to include in pre-pregnancy screening
March 13, 2025 - - Latest News -
Medicines funded by Pharmac tops 50 since last year's budget boost
March 13, 2025 - - Latest News -
Australia is not alone in using rebate payments, but there are some differences
March 13, 2025 - - Latest News -
Australian company confirms the location of key clinical trial
March 13, 2025 - - Australian Biotech